Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 29, 2004. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares, specifically regarding the GlaxoSmithKline US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes within a specific employee retirement fund.
Material Changes
The primary material change reported is a decrease in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan. As of October 28, 2004, the fund's holdings changed from 18,944,032 to 18,880,103 shares. This movement occurred at an average price of $41.62 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that two directors, Dr. J.P. Garnier and Dr. T. Yamada, are potentially interested in the shares held in the fund in the same manner as other employees or former employees.
Investor Verification Points
- Verify the impact of the 64,929 share reduction in the US Retirement Savings Plan on overall director ownership disclosures.
- Confirm the average transaction price of $41.62 against market data for October 28, 2004.
- Review the full 20-F annual report for comprehensive financial performance data, as this 6-K does not contain financial statements.